AASLD 2025 Reflections: Key takeaways in primary sclerosing cholangitis
Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.
AASLD 2025 Reflections: Key takeaways in primary biliary cholangitis
Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.
Seladelpar improves wellbeing and lowers itch impact
Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.
Ongoing seladelpar treatment continues to benefit PBC patients
Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.
Sustained responses to elafibranor in PSC
Mitchell Shiffman comments on ELMWOOD findings for elafibranor in PSC.
PRO-C3 may illuminate liver disease progression in PBC
A correlation between PRO-C3 and liver measures in PBC suggests it could represent a novel disease biomarker.
Long-term elafibranor therapy improves PBC outcomes
ELATIVE open-label extension trial findings support long-term elafibranor treatment in patients with PBC.
Seladelpar cholestasis benefits extend long term
Discussing the ASSURE findings for seladelpar in PBC with Daniel Pratt.
Real-world data support seladelpar use in PBC patients switching from obeticholic acid
Real-world evidence supports seladelpar use in patients with PBC initiating seladelpar second-line or switching from obeticholic acid.
Responses to elafibranor in primary sclerosing cholangitis maintained after initial treatment
An open-label trial extension showed that the PPAR agonist elafibranor maintained efficacy, and former placebo patients saw improvements.
Elafibranor improves symptom burden, unaffected by BMI
Andreas Kremer discusses post-hoc analyses from the ELATIVE trial showing independent improvement in patient-reported outcomes with elafibranor for patients with PBC and efficacy irrespective of BMI.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
Comprehensive PBC management: innovative and personalized plans to enhance patient outcomes
Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.
Navigating Challenges in PBC Management: Focus on Inadequate Responders and Symptomatic Itching
In this case study module, Marlyn Mayo discusses 3 short patient profiles to illustrate difficult situations when treating patients with PBC including managing inadequate response to initial therapy and symptomatic itching.
Breaking down PBC: a comprehensive guide
Led by Kris Kowdley, this interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) provides details on the pathogenesis, diagnosis, management and latest clinical data for PBC. Click through the sections, or download the PDF to use as a guide in your clinic.
Breaking down PBC: a comprehensive guide
Interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) providing details on the pathogenesis, diagnosis, management and latest clinical data.
Combination therapies and real world treatment for PBC patients
Dr Adriaan Van der Meer shares his insights on the results from the combination trial of obeticholic acid and bezafibrate for PBC patients, presented at EASL 2024 in Milan, Italy. In addition, discover key findings and learn about the RECAPITULATE trial, focusing on real-world treatment outcomes.
Breaking analysis of ASSURE from EASL 2024
Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.
ELATIVE updates from EASL 2024
Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.
‘Rapid and durable response’ with seladelpar in patients with PBC and cirrhosis
ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.
Biochemical response benefits with elafibranor are ‘consistent’ for PBC
ELATIVE subanalysis confirms improved biochemical response with elafibranor over placebo for primary biliary cholangitis according to various different criteria.
Adding obeticholic acid to slow-release bezafibrate shows promise for PBC
Combining slow-release bezafibrate with obeticholic acid shows treatment potential for patients with primary biliary cholangitis.
ELATIVE trial shows pruritus benefits with elafibranor in PBC
ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.
The evolving landscape of PBC: new therapies and future directions
Kris Kowdley and David Jones share their insights on the evolving landscape of PBC, including new and upcoming therapy options, and how these may change practice for the disease.
Barriers and symptoms burden: the unmet needs in PBC
Drs Marlyn Mayo and Gideon Hirschfield discuss the unmet needs in PBC management, highlighting the significant burden that symptoms pose for patients, the importance of monitoring and a patient-centric management approach offering insights into what might lie ahead in 2024.
The Liver Meeting 2023 – updates to the current landscape
Dr Palak Trivedi joins Dr Gideon Hirschfield to explore pivotal insights from The Liver Meeting 2023. Together, they highlight crucial updates, unveil novel findings, and deliver a concise overview of the current landscape of PBC.
Andreas Kremer discusses advances in second-line obeticholic acid
Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.
Kris Kowdley’s analysis of breakthrough research on PBC
Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.
Gideon Hirschfield highlights noteworthy findings on PBC
Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.
ELATIVE: Elafibranor shows treatment efficacy in patients with PBC
ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.
Positive RESPONSE for seladelpar in patients with PBC
RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.
Adding bezafibrate to OCA shows treatment promise for PBC
Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.
